Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Lisa Hochman

Dermatology Morristown, NJ Medical Doctor

NPI 1992799134 CMS profile 181008

290 Madison Ave, Morristown, NJ 07960

Open in the dashboard

General payments

$1,326

55 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lisa Hochman of Morristown, NJ is reported in the CMS Open Payments database as having received $1,326 across 55 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 38th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $218 7
2022 General $149 3
2021 General $410 17
2020 General $114 8
2019 General $435 20

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lisa Hochman
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Lisa Hochman were reported at $218. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Lisa Hochman Dermatology median Middle half National median
2019 $435 $454 $129–$1,240 $163
2020 $114 $235 $81–$756 $114
2021 $410 $377 $108–$1,108 $132
2022 $149 $514 $143–$1,391 $149
2023 $0 $607 $159–$1,674 $160
2024 $0 $751 $204–$1,903 $164
2025 $218 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Regeneron Healthcare Solutions, Inc. $326 11 payments
  2. Ortho Dermatologics, a division of Bausch Health US, LLC $221 8 payments
  3. Journey Medical Corporation $161 4 payments
  4. Lilly USA, LLC $134 6 payments
  5. Janssen Biotech, Inc. $105 1 payment
  6. LEO Pharma Inc. $87 6 payments
  7. Krystal Biotech Inc $66 4 payments
  8. Amgen Inc. $42 3 payments
  9. Pfizer Inc. $41 3 payments
  10. Dermira, Inc. $29 2 payments
  11. Other $116 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,226 54 payments
  2. Education $100 1 payment
Products named General payments · program years 2019–2025
  1. DUPIXENT $326 11 payments
  2. DUOBRII $180 5 payments
  3. TALTZ $134 6 payments
  4. TREMFYA $105 1 payment
  5. SIMPONI ARIA $105 1 payment
  6. VYJUVEK $66 4 payments
  7. ENSTILAR $58 4 payments
  8. Otezla $42 3 payments
  9. EUCRISA $41 3 payments
  10. BRYHALI $29 2 payments
  11. Other $264 18 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

317

Median for Dermatology: 534

Drug cost

$381,587

Median for Dermatology: $67,151

Branded share of claims

27.8%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 52 $181,854
Otezla Apremilast Brand 25 $114,760
Humira(Cf) Pen Adalimumab Brand 11 $74,927
Fluorouracil Generic 75 $3,951
Tacrolimus Generic 25 $2,362
Fluocinolone Acetonide Generic 30 $1,314
Imiquimod Generic 19 $1,141
Clobetasol Propionate Generic 13 $655
Ketoconazole Generic 22 $341
Minoxidil Generic 19 $124

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 28 billing codes

Paid by Medicare

$40,582

Medicare's payments for the services billed

Medicare patients

307

Average age 75

Services billed

1,027

200 women, 107 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 60%
Arthritis 48%
Ischemic heart disease 23%
Osteoporosis 23%
Diabetes 19%
Cancer 15%
Depression 15%
Atrial fibrillation 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

55 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record